Antiretroviral Therapy, Highly Active
"Antiretroviral Therapy, Highly Active" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor.
| Descriptor ID |
D023241
|
| MeSH Number(s) |
E02.319.310.075
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antiretroviral Therapy, Highly Active".
Below are MeSH descriptors whose meaning is more specific than "Antiretroviral Therapy, Highly Active".
This graph shows the total number of publications written about "Antiretroviral Therapy, Highly Active" by people in this website by year, and whether "Antiretroviral Therapy, Highly Active" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 7 | 0 | 7 |
| 2005 | 3 | 0 | 3 |
| 2006 | 3 | 1 | 4 |
| 2007 | 2 | 2 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 2 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 3 | 4 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 2 | 4 |
| 2016 | 4 | 3 | 7 |
| 2017 | 2 | 1 | 3 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antiretroviral Therapy, Highly Active" by people in Profiles.
-
Variation in blood microbial lipopolysaccharide (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV. EBioMedicine. 2022 Jun; 80:104037.
-
IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. AIDS Res Hum Retroviruses. 2021 03; 37(3):184-188.
-
Improving the Youth HIV Prevention and Care Cascades: Innovative Designs in the Adolescent Trials Network for HIV/AIDS Interventions. AIDS Patient Care STDS. 2019 09; 33(9):388-398.
-
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 06; 6(6):e364-e372.
-
Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res. 2018; 16(2):143-150.
-
Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth. Antivir Ther. 2018; 23(4):315-324.
-
The effect of plasma auto-IgGs on CD4+ T cell apoptosis and recovery in HIV-infected patients under antiretroviral therapy. J Leukoc Biol. 2017 12; 102(6):1481-1486.
-
Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy. J Infect Dis. 2017 07 01; 216(1):82-91.
-
Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation. Antivir Ther. 2017; 22(8):669-680.
-
The induction of CD80 and apoptosis on B cells and CD40L in CD4+ T cells in response to seasonal influenza vaccination distinguishes responders versus non-responders in healthy controls and aviremic ART-treated HIV-infected individuals. Vaccine. 2017 02 01; 35(5):831-841.